BR112021017495A2 - Derivado de pirazina e sua aplicação na inibição de shp2 - Google Patents
Derivado de pirazina e sua aplicação na inibição de shp2Info
- Publication number
- BR112021017495A2 BR112021017495A2 BR112021017495A BR112021017495A BR112021017495A2 BR 112021017495 A2 BR112021017495 A2 BR 112021017495A2 BR 112021017495 A BR112021017495 A BR 112021017495A BR 112021017495 A BR112021017495 A BR 112021017495A BR 112021017495 A2 BR112021017495 A2 BR 112021017495A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrazine derivative
- application
- shp2
- inhibition
- shp2 inhibition
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title abstract 4
- 150000003216 pyrazines Chemical class 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 abstract 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 abstract 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
derivado de pirazina e sua aplicação na inibição de shp2. a presente invenção está relacionada a um derivado de pirazina, a uma aplicação deste na inibição de shp2 e a um composto de fórmula (i), ou sais farmaceuticamente aceitáveis, ésteres, isômeros, solvatos, pró-fármacos ou marcadores isotópicos deste. a estrutura do composto de fórmula (i) é como apresentada a seguir. o novo derivado de pirazina fornecido pela presente invenção possui excelente atividade de inibição de shp2 e pode ser usado para evitar e/ou tratar doenças ou distúrbios mediados ou dependentes de proteína tirosina quinase fosfatase não receptora.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910160960.7A CN111647000B (zh) | 2019-03-04 | 2019-03-04 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| PCT/CN2020/077391 WO2020177653A1 (zh) | 2019-03-04 | 2020-03-02 | 吡嗪类衍生物及其在抑制shp2中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017495A2 true BR112021017495A2 (pt) | 2021-12-14 |
Family
ID=72337672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017495A BR112021017495A2 (pt) | 2019-03-04 | 2020-03-02 | Derivado de pirazina e sua aplicação na inibição de shp2 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220127276A1 (pt) |
| EP (1) | EP3936502A4 (pt) |
| JP (1) | JP2022523786A (pt) |
| KR (1) | KR20210135561A (pt) |
| CN (2) | CN111647000B (pt) |
| AU (1) | AU2020233038A1 (pt) |
| BR (1) | BR112021017495A2 (pt) |
| CA (1) | CA3132395A1 (pt) |
| CL (1) | CL2021002308A1 (pt) |
| CO (1) | CO2021013140A2 (pt) |
| IL (1) | IL286069A (pt) |
| MX (1) | MX2021010625A (pt) |
| SG (1) | SG11202109603SA (pt) |
| WO (1) | WO2020177653A1 (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019346118B2 (en) | 2018-09-29 | 2024-05-16 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of SHP2 |
| WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| WO2022006780A1 (en) * | 2020-07-08 | 2022-01-13 | Novartis Ag | Manufacture of compounds and compositions for inhibiting activity of shp2 |
| IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
| PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
| AU2022271243A1 (en) * | 2021-05-05 | 2023-11-30 | Huyabio International, Llc | Combination therapies comprising shp2 inhibitors and pd-1 inhibitors |
| WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4333850A1 (en) * | 2021-05-05 | 2024-03-13 | Huyabio International, LLC | Shp2 inhibitor monotherapy and uses thereof |
| CA3217092A1 (en) * | 2021-05-05 | 2022-11-10 | Farbod Shojaei | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors |
| CN115340559A (zh) * | 2021-05-12 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶杂环类抑制剂的制备及其应用 |
| CN115340561A (zh) * | 2021-05-14 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶稠环类抑制剂的制备及其应用 |
| AU2022274936A1 (en) * | 2021-05-13 | 2023-12-07 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic compound for inhibiting shp2 activity, preparation method therefor and use thereof |
| TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023122938A1 (en) * | 2021-12-28 | 2023-07-06 | Js Innomed Holdings Ltd. | Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| CN115521305A (zh) * | 2022-09-20 | 2022-12-27 | 中国药科大学 | Shp2&nampt双靶向化合物及其药物组合物和用途 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| CN115677661B (zh) * | 2022-10-27 | 2024-04-19 | 中国药科大学 | 杂环硫醚类化合物及其用途和药物组合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| EP3310774B1 (en) * | 2015-06-19 | 2020-04-29 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| KR20230109185A (ko) | 2016-06-07 | 2023-07-19 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| WO2017216706A1 (en) * | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| CN109983001B (zh) | 2016-07-12 | 2023-04-04 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
| WO2018130928A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| JP6878615B2 (ja) | 2017-03-23 | 2021-05-26 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体 |
| AU2018328273A1 (en) | 2017-09-07 | 2020-03-12 | Revolution Medicines, Inc. | SHP2 inhibitor compositions and methods for treating cancer |
| AU2018347516A1 (en) | 2017-10-12 | 2020-05-07 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
| US11110171B2 (en) | 2017-12-21 | 2021-09-07 | New York University | PD-1 related cancer therapy |
| US11426422B2 (en) | 2018-01-30 | 2022-08-30 | Research Development Foundation | SHP2 inhibitors and methods of use thereof |
| AU2019239658A1 (en) | 2018-03-21 | 2020-11-12 | Suzhou Puhe BioPharma Co., Ltd. | SHP2 inhibitors and uses thereof |
| SG11202009793TA (en) | 2018-04-10 | 2020-10-29 | Revolution Medicines Inc | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
-
2019
- 2019-03-04 CN CN201910160960.7A patent/CN111647000B/zh active Active
-
2020
- 2020-03-02 AU AU2020233038A patent/AU2020233038A1/en active Pending
- 2020-03-02 BR BR112021017495A patent/BR112021017495A2/pt unknown
- 2020-03-02 EP EP20766519.1A patent/EP3936502A4/en active Pending
- 2020-03-02 KR KR1020217031808A patent/KR20210135561A/ko unknown
- 2020-03-02 MX MX2021010625A patent/MX2021010625A/es unknown
- 2020-03-02 US US17/436,223 patent/US20220127276A1/en active Pending
- 2020-03-02 SG SG11202109603S patent/SG11202109603SA/en unknown
- 2020-03-02 JP JP2021551865A patent/JP2022523786A/ja active Pending
- 2020-03-02 WO PCT/CN2020/077391 patent/WO2020177653A1/zh unknown
- 2020-03-02 CN CN202080014053.2A patent/CN113474338A/zh active Pending
- 2020-03-02 CA CA3132395A patent/CA3132395A1/en active Pending
-
2021
- 2021-09-02 IL IL286069A patent/IL286069A/en unknown
- 2021-09-03 CL CL2021002308A patent/CL2021002308A1/es unknown
- 2021-09-30 CO CONC2021/0013140A patent/CO2021013140A2/es unknown
-
2023
- 2023-01-25 US US18/101,511 patent/US11827644B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210135561A (ko) | 2021-11-15 |
| WO2020177653A1 (zh) | 2020-09-10 |
| CN111647000A (zh) | 2020-09-11 |
| CN111647000B (zh) | 2021-10-12 |
| CL2021002308A1 (es) | 2022-05-20 |
| CN113474338A (zh) | 2021-10-01 |
| MX2021010625A (es) | 2021-10-26 |
| CO2021013140A2 (es) | 2021-11-30 |
| SG11202109603SA (en) | 2021-10-28 |
| US11827644B2 (en) | 2023-11-28 |
| AU2020233038A1 (en) | 2021-10-21 |
| EP3936502A1 (en) | 2022-01-12 |
| IL286069A (en) | 2021-10-31 |
| EP3936502A4 (en) | 2023-02-15 |
| CA3132395A1 (en) | 2020-09-10 |
| US20230227464A1 (en) | 2023-07-20 |
| JP2022523786A (ja) | 2022-04-26 |
| US20220127276A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021017495A2 (pt) | Derivado de pirazina e sua aplicação na inibição de shp2 | |
| BR112023015527A2 (pt) | Inibidores de cdk e métodos de uso destes | |
| BR112021022457A2 (pt) | Inibidores de fgfr e métodos de uso dos mesmos | |
| CL2022000751A1 (es) | Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419) | |
| ZA202102628B (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| BR112023020483A2 (pt) | Compostos para inibir nlrp3 e usos dos mesmos | |
| BR112019019193A2 (pt) | compostos de pirimidinil-piridilóxi-naftila e métodos para tratar de doenças e distúrbios relativos a ire-1 | |
| PE20231073A1 (es) | Inhibidores de pi3k y metodos de uso de los mismos | |
| BR112012004453A8 (pt) | composto inibidor de proteína quinase, sua composição farmacêutica e seu uso | |
| BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
| CO2021015614A2 (es) | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 | |
| DOP2017000117A (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| CL2022003544A1 (es) | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8 | |
| BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| NZ756603A (en) | Selective hdac6 inhibitors | |
| BR112018005861A2 (pt) | derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos | |
| AR090241A1 (es) | INHIBIDORES DE LA b-SECRETASA | |
| BR112022010754A2 (pt) | Análogos de rapamicina e usos dos mesmos | |
| NZ754764A (en) | Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses | |
| BR112017008312A2 (pt) | novos compostos de piridopirimidinona para modular a atividade catalítica de histona lisina demetilases (kdms) | |
| BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
| BR112019007543A2 (pt) | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase | |
| AR126447A1 (es) | INHIBIDORES DE PI3Ka Y MÉTODOS DE USO DE LOS MISMOS | |
| BR112022009710A2 (pt) | Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2 | |
| CL2021003292A1 (es) | Inhibidores de prmt5. |